title: Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk for Bleeding.
abstract: Low/medium-bleeding-risk populations undergoing percutaneous coronary intervention (PCI) show significantly less bleeding with bivalirudin (BIV) than with unfractionated heparin (UFH), but this has not been established for high-risk patients. We performed a randomized double-blind prospective trial comparing efficacy and safety of BIV versus UFH combined with dual antiplatelet therapy during PCI among 100 high-risk patients with non-ST elevation myocardial infarction (NSTEMI) or angina pectoris. The baseline characteristics were similar in both treatment arms. A radial approach was used in 84% of patients with a higher rate in the BIV group (90 vs. 78%, p < 0.05). Study end points were: major and minor bleeding, port-of-entry complications, major adverse cardiac events (MACE) in-hospital, and at long-term follow-up. There was one case of major gastrointestinal bleeding in the BIV group and 7% minor bleeding complications in both categories. Rate of periprocedural myocardial infarction (PPMI) in the BIV group was twice that in the UFH group (20 vs. 10%, p < 0.16). In-hospital MACE rate was higher in BIV patients as well (12 vs. 2%, p = 0.1). By univariate analysis, the femoral approach was the predictor of PPMI and in-hospital MACE. In a multivariate model, the independent predictor of PPMI was previous MI (odds ratio, 7.7; p < 0.0158). PPMI was 49.7 times more likely with the femoral approach plus BIV than the nonfemoral approach plus UFH (p < 0.0021). At 41.5 ± 14 months' follow-up, end points did not significantly differ between the groups. In patients at high risk for bleeding undergoing PCI, BIV was not superior to UFH for bleeding complications, and early and late clinical outcomes.
authors.affiliation: Heart Institute, Ha'Emek Medical Center, Afula, Israel.
authors.forename: Alexander
authors.initials: A
authors.lastname: Feldman
authors.affiliation: Heart Institute, Ha'Emek Medical Center, Afula, Israel.
authors.forename: Khalid
authors.initials: K
authors.lastname: Suleiman
authors.affiliation: Heart Institute, Ha'Emek Medical Center, Afula, Israel.
authors.forename: Limor
authors.initials: L
authors.lastname: Bushari
authors.affiliation: Heart Institute, Ha'Emek Medical Center, Afula, Israel.
authors.forename: Malka
authors.initials: M
authors.lastname: Yahalom
authors.affiliation: Heart Institute, Ha'Emek Medical Center, Afula, Israel.
authors.forename: Ehud
authors.initials: E
authors.lastname: Rozner
authors.affiliation: Heart Institute, Ha'Emek Medical Center, Afula, Israel.
authors.forename: Nahum Adam
authors.initials: NA
authors.lastname: Freedberg
authors.affiliation: Heart Institute, Ha'Emek Medical Center, Afula, Israel.
authors.forename: Yoav
authors.initials: Y
authors.lastname: Turgeman
keywords: PCI; bivalirudin; bleeding; high-risk patient; unfractionated heparin